Introduction
With advancement in gene technology and, more recently, gene therapy, it is now believed that gene transfer technologies could be misused for improvement of athletic performance in sport. 1 This new form of doping, termed gene doping, aims at enhancement of sporting prowess by 'transfer of cells or genetic elements or the use of pharmacological or biological agents that alter gene expression' (http://www.wada-ama.org/ Documents/World_Anti-Doping_Program/WADP-Prohibitedlist/WADA_Prohibited_List_2010_EN.pdf). In its most obvious form, gene doping is realized by the introduction into an athlete's body of a synthetic human gene capable of producing an additional amount of a performanceenhancing protein.
One major attraction of gene doping over conventional doping with drugs or recombinant proteins is the difficulty of detecting its use. 2 This view is based on the assumption that the introduced gene (the transgene) and the protein expressed from it (the transgenic protein) would be almost identical to their endogenous counterparts, making it difficult to identify a detection target for testing. In addition, as muscle is likely to be the target tissue for the transgene administration, there have been suggestions that reliable gene doping testing would require muscle biopsy, a procedure not applicable to sport. Although detection of gene doping poses a significant technical challenge, several possible strategies have been proposed and are being pursued. 2 The strategies fall into two major categories, direct and indirect approaches, with direct methods targeting the doping agent or the transgenic protein, whereas indirect methods aim at detecting responses of the body to a doping agent. 2 In view of legal implications associated with any method for monitoring doping by athletes, direct methods are always preferable over indirect methods. 2, 3 A suitable test for gene doping should be applicable to a sample that is easily accessible for collection, for example, blood or urine, and that would contain a detection target for a prolonged period of time. A detection method should be highly specific, sensitive and be properly validated to be able to withstand legal scrutiny. Of additional advantage would be the potential for the method to be fast, cost-effective and to allow high-throughput analysis.
In this study, we developed a novel methodology for direct detection of the transgene and evaluated its feasibility for gene doping detection in blood samples from athletes. The rational of this approach ( Figure 1 ) is founded on subtle differences between the sequences of a 'doping' transgene and its endogenous counterpart in genomic DNA (gDNA). The vast majority of human genes, including candidates for gene doping, contain exons and introns. In gene therapy, and potentially gene doping, transgenes are usually derived from the complementary DNA (cDNA) for the gene to be transferred and cDNA does not contain introns. We proposed that molecular tests based on real-time PCR can be specifically designed to detect target sequences within the transgene corresponding to exon/exon junctions in cDNA that are absent in gDNA due to their interruption by introns. This, together with the high sensitivity of PCR due to its exponential amplification of the target, allowed us to hypothesize that such an approach would allow detection of a small amount of transgene in a large background of the endogenous gene in gDNA. Moreover, the use of real-time PCR that allows a one-step analysis in a closed system will prevent any possible contamination of a sample that may potentially lead to a false-positive test, further strengthening the suitability of such strategy to form the basis for a gene doping test.
On the basis of the prediction that erythropoietin (EPO) is likely to be among the first candidates for gene doping, we chose EPO as a model gene. To develop and test the proposed approach for gene doping detection, we used a model in vitro system that comprises human gDNA (hgDNA) as a source of the endogenous EPO gene, and EPO cDNA (cDNA-EPO) incorporated in a plasmid to simulate the EPO transgene in a gene therapy vector. We designed and developed several assays based on real-time PCR to detect cDNA-EPO. Two developed PCR assays, with the best performance parameters and one commercial gene expression assay for EPO, were validated for detection of cDNA-EPO in a background of endogenous EPO gene in hgDNA. On the basis of the minimal amounts detectable by these assays and analysis of literature on persistence of transferred genetic material in blood from the subjects participating in gene therapy studies, we concluded that the developed approach could be suitable to detect gene doping by gene transfer by analysis of small volumes of blood using regular outof-competition testing.
Results
Desktop selection and design of real-time PCR assays for specific detection of cDNA-EPO Before designing PCR assays (further referred to as 'assays' or 'detectors') targeting exon/exon junctions in cDNA-EPO for specific detection of EPO transgene with no or minimal crossreactivity to endogenous human EPO gene, a search of literature (PubMed database, NCBI (http://www.ncbi.nlm.nih.gov/sites/entrez)), relevant assay databases (qPrimerDepot (http://primerdepot.nci. nih.gov/), PrimerBank (http://pga.mgh.harvard.edu/ primerbank/), RTPrimerDB (http://medgen.ugent.be/ rtprimerdb/) and real-time PCR primer sets (http://www. realtimeprimers.org/) and commercial predesigned gene expression assays (Applied Biosystems (http://www. appliedbiosystems.com.au); Roche (http://www.rocheapplied-science.com/sis/rtpcr/upl); QIAGEN (http:// www1.qiagen.com/geneglobe) was conducted. In the search, the main assay requirement was that one or both primer(s) and/or a probe crossed an exon/exon junction. One of nine commercial gene expression assays for human EPO available at the time of the study (Hs01071097_m1, further referred to as Assay 1) appeared to be potentially suitable for our objective and was selected as a reference for assays developed in this study.
De novo PCR assays specific for cDNA-EPO but not for hgDNA-EPO were designed using several programs. Each detector was given a number followed, in parentheses, by exon location of a forward (F) primer, a probe (P) and a reverse (R) primer. For example, for Assay 2 (F3-P3/4-R4), the forward and reverse primers lie within exons 3 and 4 of cDNA-EPO, respectively, whereas the probe spans exon 3/exon 4 junction. The newly designed assays, together with those selected from the literature and assays' databases, were prioritized for experimental screening, based on the results of theoretical assessment of factors that may affect assay performance. Six first choice assays, incidentally all from de novo designed assays, were selected for experimental evaluation.
Screen and initial evaluation of designed detectors for performance in detecting cDNA-EPO Selected assays (six in total) were optimized with the focus on concentrations of primers and probe, temperature (T an/ext ) and duration (t an/ext ) of the combined annealing/extension step and brand of PCR Master Mix. The effect of performing annealing and extension separately at two different temperatures was tested and was shown not to provide additional benefit for assays' performance. Following optimization, the assays were evaluated using key PCR performance parameters including specificity for detection of cDNA-EPO as well as minimal amount detectable, efficiency, precision and linearity (the squared correlation coefficient R 2 ), based on a serial dilution calibration curve. The fresh serial dilutions of the plasmid containing human EPO gene (pDNA-EPO) were prepared volumetrically in salmon testes DNA (stDNA) for each experiment: the first five 10-fold dilutions resulted in the amount of pDNA-EPO per reaction ranging from B6 Â 10 5 to 6 copies, whereas the last dilution was prepared one in four to achieve the amount of pDNA-EPO of B1.5 copies (further rounded off to 1 copy) per reaction. Here and thereafter the number of copies of pDNA-EPO (equivalent to the number of copies of cDNA-EPO) is approximate and is calculated from dilution series prepared from the pDNA-EPO stock quantified as described in Materials and methods section. Specificity was evaluated by melt curve analysis (SYBR Green chemistry), agarose gel electrophoresis and by amplicon sequence analysis. Samples containing No Template Control (NTC), hgDNA or stDNA (at 20 ng per reaction) were used as negative controls. Four assays (among them assays 1 and 2 presented in Tables 1 and 2 ) were found to be the most Figure 1 Schematic depiction of the evaluated strategy for direct detection of EPO transgene.
Erythropoietin gene doping detection A Baoutina et al suitable for the purpose of this project: they were specific for pDNA-EPO, had efficiency close to 100%, linearity over 0.985 and high sensitivity in a background of stDNA. Three assays, despite in silico prediction of their high specificity for pDNA-EPO, amplified hgDNA in the absence of pDNA-EPO (not shown). For two assays, the sizes of the generated products, as judged from the agarose gel electrophoresis analysis, were the same as those predicted from amplification of pDNA-EPO. As this meant that amplification from the cDNA-EPO and hgDNA-EPO cannot be distinguished using these assays, further work on them was abandoned.
Amplification from hgDNA in the absence of pDNA-EPO was also observed (not shown) with assay 3 (Tables  1 and 2 ). In this case, agarose gel electrophoresis analysis demonstrated that the size of the amplicon generated from hgDNA (231 base pairs (bp)) was different from the size of the product amplified from pDNA-EPO (97 bp) and corresponded to the intron 4-containing product from the endogenous EPO gene in hgDNA. To explain the fact that the assay 3 probe, that was specifically designed to cross the exon 4/exon 5 boundary, allowed fluorescence acquisition from amplification of a nonspecific product, alignment of the probe to exon 4/intron 4 and intron 4/exon 5 DNA sequences was performed. It was revealed that the probe designed with 100% homology to the exon 4/exon 5 junction also had 87% homology to the intron 4/exon 5 junction in hgDNA-EPO. The latter was difficult to avoid during probe design, as the final three nucleotides at the end of both exon 4 and intron 4 are identical; unfortunately, software for assay design could not predict such crossreactivity.
As the sizes of the specific and nonspecific amplicons generated from cDNA-EPO and hgDNA-EPO differed by 134 bp in assay 3, we considered using this detector either as an end point PCR, when, subsequent to PCR, the amplicons are detected following gel electrophoresis analysis, or by differentiating the two amplicons based on the difference in their melting profile. The latter strategy was abandoned after melt curve analysis of the two products generated from cDNA-EPO and hgDNA-EPO on Mx3005P or Rotor-Gene 6000 PCR machines revealed that their T m were very similar. As end point PCR is usually much less sensitive than real-time PCR, Sensitivity is shown as the lowest tested amount of pDNA-EPO (in approximate copies) that was detected positive before method validation. If the lowest dilution was detected positive in one replicate (out of two), the next higher dilution is also presented. Copies of pDNA-EPO were as calculated from the dilution series, as described in Materials and methods section.
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we undertook further improvement of assay 3 to minimize hybridization of the probe to intron 4/exon 5 junction with the goal to eliminate, or to at least significantly decrease, detection of a nonspecific product. Additional optimization of T an/ext , t an/ext and of the ratio of the primers to the probe led to significant reduction of detection of the nonspecific product from hgDNA-EPO (Figure 2a ), despite its ongoing generation ( Figure 2b ). As the outcome, five detectors (among them, assays 1, 2 and 3) targeting three out of four exon/exon junctions (1/2, 3/4 and 4/5) in cDNA-EPO were selected based on their sensitivity, specificity and PCR performance to be evaluated for detection of cDNA-EPO in the presence of hgDNA.
Evaluation of selected real-time PCR assays for cDNA-EPO in the presence of hgDNA To validate the selected assays for detecting pDNA-EPO in background of hgDNA, first, the effect of the presence of increasing amounts of hgDNA on the efficiency of the assays for pDNA-EPO was tested by performing serial dilution standard curve analyses in a background of different amounts of hgDNA. In the presence of up to 400 ng hgDNA, the efficiency of PCR in the selected assays decreased by no more than 7% from the efficiency observed in stDNA, and their linearity was not lower than 0.985 (Table 3 shows results for assays 1-3 only). hgDNA present at amounts close to 1 mg significantly inhibited PCR in assay 4 (F1/2-P2-R3/4, not shown), so that amplification was only observed for high concentrations of pDNA-EPO (6 Â 10 4 and 6 Â 10 5 copies per reaction). The work on this assay was, therefore, terminated. For other assays, the efficiency of PCR also decreased, but was still above 75% and linearity was higher than 0.979. It may be expected that preparations of hgDNA from human blood for doping control may contain higher levels of PCR inhibitors than the commercial hgDNA preparation used in our model system. Therefore, for subsequent studies we limited the amount Agarose gel electrophoresis analysis of PCR amplicons generated from a mixture of pDNA and hgDNA (B6 copies and 800 ng, respectively, lanes 1 and 2) and of hgDNA alone (800 ng, lanes 3-5); L-molecular markers.
Erythropoietin gene doping detection A Baoutina et al of hgDNA per reaction to 1 mg for three assays (assays 1, 2 and assay 5 (F2-P3/4-R4, not shown)) and to 800 ng for assay 3. Lower background of hgDNA for assay 3 was chosen based on results of optimization of conditions for specific detection of cDNA-EPO in background of hgDNA shown in Figure 2 and described above. From initial specificity and sensitivity studies of the remaining four detectors in the presence of increasing amounts of hgDNA, the minimal amount of pDNA-EPO, expressed in copies per 1 mg of background hgDNA, was detected by assays 2 and 3, and was as low as B1 copy (Table 3) . Performance of commercial assay 1 was comparable with that of the assays developed in this study. Assay 4 (not shown) detected B3 copies of pDNA-EPO per 1 mg of background hgDNA. As the precision of detection of very low copy number of the target is governed by the Poisson statistics, discrimination between these low copy numbers detectable by the assays could not be performed with 95% confidence, especially with the low number of replicates analyzed at this stage of the study. 4 Therefore, the difference in sensitivity between the assays is of indicative nature only and was used to narrow down the choice of assays for validation.
Assays 1, 2 and 3 with optimal overall performance and seemingly highest sensitivity for detecting pDNA-EPO in a hgDNA background were selected for validation.
Validation of selected PCR assays for detecting pDNA-EPO in an hgDNA background During assay validation, the intra-assay repeatability, reproducibility and robustness of developed assays and the commercial assay 1 were assessed and the minimal amount detectable was validated (Table 4) .
Detailed evaluation of specificity. Specificity was first assessed by demonstrating that the amplicon generated in each assay is specific to the target DNA sequence intended by the assay design. For that, specificity was confirmed by melt curve analysis, agarose gel electrophoresis, which demonstrated the correct size of the product, and by amplicon sequence analysis. Specificity was also evaluated as the likelihood of obtaining a negative result when the measured analyte, pDNA-EPO, is not present. For assay 2, there were no false-positive results for either hgDNA when present at 1 mg per reaction (n ¼ 23) or NTC (n ¼ 14) (Table 4a) . Similarly, for assay 1, there were no false-positives for either hgDNA when present at 1 mg per reaction (n ¼ 15) or NTC (n ¼ 22). For assay 3, very low drift in acquired fluorescence was observed in some samples containing 0.8 mg of hgDNA when PCR was allowed to proceed to over 50 cycles (Figure 2b ). During the assay validation, we established and validated the manually-set fluorescence threshold for which, on completion of 50 PCR cycles, each sample of hgDNA at every tested concentration was reported as 'negative', whereas for each sample containing pDNA-EPO at concentration close to the minimal amount detectable, the C t value did not exceed 40. To further confirm that all samples of hgDNA were truly negative, the samples for which the fluorescence drift was observed over 50 amplification cycles, but did not reach the established and validated threshold of baseline fluorescence, were subjected to gel analysis. Similarly to results shown in Figure 2 , these samples contained only one band with the size of 231 bp that corresponded to the product from endogenous EPO gene from hgDNA.
Repeatability, reproducibility and robustness. The intra-laboratory variation was determined by repeating experiments on different days by different staff and using two different real-time PCR machines, Mx3005P and Rotor-Gene 6000. Robustness of the assays was evaluated by assessing the effect of deliberate variations to the assay, such as different lots of PCR master mixes, making new dilutions of reagents and slight variations in reagents' storage conditions. Results of these experiments are presented in Table 4 and demonstrate that assays 2, 3 and the commercial assay 1 are highly Sensitivity was calculated to be universally expressed per 1 mg hgDNA.
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Minimal amount detected. Next, the minimal amount of pDNA-EPO that can be detected in the highest amount of background hgDNA was estimated. For that, stock solution of pDNA-EPO was volumetrically serially diluted 1 in 10 in hgDNA (200 ng ml À1 for assay 3 or 250 ng ml À1 for assays 1 and 2) to achieve the concentration of B60 copies per 800 ng (assay 3) or per 1 mg hgDNA (assays 1 and 2) per reaction, followed by further dilutions to achieve values shown in Table 4b . When pDNA-EPO was present at the level of B11 copies in a background of either 1 mg hgDNA (assays 1 and 2) or 800 ng hgDNA (assay 3; equivalent to 14 copies of pDNA-EPO per 1 mg hgDNA), respectively, 100% of replicates were tested positive.
The determined minimal amount detectable when expressed relevant to number of human genomes or copies of endogenous EPO gene present in hgDNA background was B1 copy of pDNA-EPO in 27 000 copies of endogenous EPO gene, for assays 1 and 2. For assay 3, it was B1 copy of pDNA-EPO in 21 000 copies of endogenous EPO. This corresponds to the ability to detect cDNA-EPO present in a sample at the level of 0.004% (copy number pDNA-EPO/copy number hgDNA-EPO) (assays 1 and 2) and 0.005% (assay 3) of background human endogenous EPO gene. As was pointed out above, due to Poisson distribution of molecules at low concentration, this difference in minimal detectable amounts between the three assays is of indicative nature only and is not statistically significant. It can be concluded that all three assays had extremely high sensitivity (B0.005%) for detection of the transgene with 100% specificity in background of endogenous analogous gene. Moreover, the assays are able to detect close to 1 copy of the transgene in the presence of 1 mg of gDNA (Table 3) , and the existence of negative replicates can be explained by sampling errors arising from the stochastic distribution of low copy number template molecules. 4 
Design and validation for performance of PCR assays for detection of hgDNA-EPO
The likelihood of detecting gene doping based on analysis of DNA extracted from athletes' blood will crucially depend on the quality of DNA preparation. To confirm integrity of extracted DNA, to ensure the correct amount of starting material is used in the PCR assay and to monitor amplification and detection systems, we developed an intron-specific PCR assay for hgDNA-EPO. A SYBR Green hgDNA-EPO assay was designed using Beacon Designer.
When used with serial dilutions of hgDNA, the assay was linear (R 2 ¼ 0.989, 0.999, n ¼ 2) over a range of concentrations from 0.1 to 100 ng per reaction that corresponds to B55 to 5.5 Â 10 4 copies of hgDNA-EPO. The efficiency of the assay in two independent experiments was 95 and 112%. When present at 1 or 2 mg per reaction, hgDNA had an inhibitory effect on PCR. The specificity of the assay for hgDNA-EPO was confirmed by the lack of generation of a product with the correct T m in negative control samples of stDNA, NTC or pDNA-EPO.
Discussion
We developed several highly specific and sensitive PCR assays to detect very low amounts of EPO transgene based on cDNA-EPO in a background of hgDNA. Assays 2 and 3 allowed detection of B1 copy of cDNA-EPO in a background of 27 000 or 21 000 copies of endogenous EPO gene in hgDNA, respectively, that corresponds to B11 or 14 copies of cDNA-EPO per 1 mg of hgDNA. The commercial gene expression assay 1 had similar sensitivity to assay 2. The minimal amount Erythropoietin gene doping detection A Baoutina et al detected by each assay was validated at 100% specificity for cDNA-EPO with 0% false-positive results for hgDNA in a simple in vitro system used in this study (for n values, see Table 4 ).
To assess the feasibility of using the developed approach for direct detection of gene doping, we analyzed the data on detection of vectors by PCR from gene therapy studies on vector biodistribution and persistence in animal models and in humans available in the literature (Table 5) . In this analysis, a major focus was on reports in which intramuscular or intravascular vector administration was used, as these are the most likely administration routes in a sport setting. It must be stressed that comparison of the sensitivity of the developed assays 2 and 3 and commercial assay 1 with that reported in the literature and conclusions drawn from it should be interpreted with caution, as they would be affected by a large number of factors not taken into account in this assessment. Among them are the nature, amount and formulation of a vector, its administration route, body weight of subjects under investigation, preparation and quality of the sample and detection method itself and its validation.
In one clinical trial, 5, 6 the nonviral vector was detected in some patients' plasma at days 3, 5 and 7 and in one patient at days 30 and 60 after intramuscular injection with the assay capable of detecting 10 copies per 10 ml plasma extract. In another trial, recombinant adenoassociated viral vector (rAAV) delivered through intramuscular injection was detected in the serum of all eight subjects at day 1 or 2, of four subjects on day 7 and of one subject, up to 12 weeks after injection using PCR assay that had sensitivity of 50 copies of vector DNA per 1 mg of DNA extract from 1 or 2 ml of blood. 7 Brantly et al. 8 reported detection of rAAV-vector DNA in the blood of some subjects on days 1 and 3 and in one subject on day 14 after vector administration, using a real-time PCR assay with sensitivity of 100 copies per mg of input DNA. When rAAV was administered through the hepatic artery to target the liver in another human trial, 9 the vector was detected in serum 1 week after administration in seven subjects (out of eight tested) from all dose groups with PCR assay capable to reliably detect as few as 100 copies of vector DNA in 1mg hgDNA. In some subjects, the serum was positive for the vector 4 weeks and in one patient in the high-dose group 14 weeks after injection. In this trial, the vector could be detected in peripheral blood mononuclear cells for up to 20 weeks post-administration. 9 Animal gene therapy studies, in which vector persistence in blood after intramuscular or intravenous administration was studied and sensitivity of a method for vector detection was provided or could be deduced, were also analyzed to assess the feasibility of using the assays developed in this project for gene doping control. Conclusions drawn from this comparison are of indicative nature only and should be interpreted with even more caution than those from analysis of results from human trials. In addition to the factors mentioned above that affect the comparison of human trials, other speciesrelated factors complicate comparison of results from studies with different species. 1 Some of these are the anatomical and size differences in terms of composition and activity of muscles and their microcirculation, the efficiency of promoter/enhancer of vectors used, differences in immune response between species, general metabolic aspects and life duration.
In two murine studies, blood was positive for a plasmid in some animals for 1-2 days and up to 1 or 4 weeks after intramuscular or intravenous administration. 10, 11 The sensitivity of PCR methods used in these studies was 1000 or 100 vector copies per mg of gDNA. In another study with mice injected rAAV intramuscularly, 12 whole blood samples from a high-dose group tested positive for viral DNA until day 28, but viral DNA in plasma was cleared within 3-4 days. The sensitivity of the method for vector detection in this study is comparable to that for the assays developed here. After intravenous injection in mice, recombinant adenoviral vector DNA was detected in blood 2 days later by method with detection limit of 1 Â 10 7 recombinant adenoviral vector particles per mouse or, as we calculated, of B1 Â 10 7 recombinant adenoviral vector particles per ml blood. 13 Of note, in one murine study in which rAAV carrying a human EPO transgene was injected into a salivary gland, on average 34 400 or 53 380 copies of a vector were detected in 10 ml of DNA extract from male and female mice, respectively, 3 days after the vector administration using assay with sensitivity similar to that achieved in this study. 14 Several studies with large animals (dogs, macaques and cynomolgus monkeys) were also used to assess the feasibility of applying the developed approach for gene doping detection. As summarized in Table 5 , following intramuscular or intravenous delivery, rAAV or recombinant adenoviral vector was detected in serum or blood within several days and in peripheral blood mononuclear cells up to 10 months at levels significantly exceeding the minimal amounts detectable by the assays developed in our study. [15] [16] [17] [18] [19] Comparing performance parameters of assays 1, 2 and 3 with data from gene therapy clinical trials and animal studies for which details of a method for vectors detection and results on vector persistence are available (Table 5) , we concluded that direct detection of gene doping through gene transfer using the approach developed and tested in this project is feasible. As evidenced from the referenced papers, viral and nonviral vectors could be detected in blood components days, weeks and sometimes even months after vector transfer using PCR methods whose sensitivity was similar or lower (between several or hundred(s) times) than that of assays 1, 2 and 3. From these vector persistence data, it may be proposed that the developed approach will be valid if sampling is performed within a relatively short period (day(s) or perhaps weeks) after the doping event, which could be achieved with regular out-of-competition testing regimes. Such out-of-competition testing is currently used in control for doping with several shortlived agents including recombinant EPO protein.
The significance of this study is manyfold. It serves as a 'proof of principle' for using the described approach to directly detect gene doping. The same approach can be used to develop detection methods for other potential candidate genes for gene doping within a relatively short time frame. As the proposed approach is designed to detect cDNA for the 'doping' gene rather than any other sequence incorporated into a transgene, for example, a promoter or a regulatory sequence, it is not specific to a certain construct or a vector. In addition, this approach f Although this delivery route is unlikely relevant to gene doping, the data on the vector detection are of importance in the context of this study.
h
The data, expressed in the cited paper as viral particles per mouse, were converted to viral particles per ml of blood, assuming that blood volume in a mouse is B1.1 ml for the body weight of 20 g (http://www.informatics.jax.org/mgihome/other/mouse_facts1.shtml).
Erythropoietin gene doping detection A Baoutina et al may lead to the development of methods for gene doping testing, which will be direct, highly specific, sensitive and, when combined with multiplex technology, fast thus allowing high-throughput analysis. Moreover, the amplicons generated by the developed PCR assays may be used in the development of transgenespecific DNA targets for gene doping detection using affinity-based biosensors. 20 It is also important to note that there are potential limitations of this approach to gene doping detection. Its effectiveness may be compromised if, in order to conceal doping, the cDNA-EPO sequence is modified by insertion of small introns in a targeted exon/exon junction or by site-directed mutagenesis of sequences for primers and/or probe annealing. To address this limitation, we are now developing additional assays to target different exon/exon junctions in cDNA-EPO so that at least one assay is available for each junction. Extensive modifications of cDNA-EPO by changing all four exon/exon junctions, which will mask such a transgene for detection by the developed methodology, not only may require extensive time to be realized but may also present serious challenges to efficient transgene expression and to achieving the desired performance-enhancing effect. The resultant from intron-insertion increase in transgene size may conflict with the limited viral vector packaging capacity. Also, as mRNA splicing is target tissue-and cell-specific, the presence of introns (native or foreign) in the transgene may result in aberrant splicing when the transgene is expressed ectopically (as in the case of EPO expression in muscle rather than in its natural site of production, the kidney), potentially leading to a nonfunctional protein. It can also be hypothesized that the developed gene doping detection approach may be confounded by the presence of processed pseudogenes in a genome of some individuals leading to a falsepositive result. However, as no pseudogenes for EPO have been reported for human genome and the developed assays were negative in 100% analyses of several batches of hgDNA extracted from blood from multiple anonymous donors, we believe this is an unlikely possibility. Nevertheless, as part of our ongoing work, we continue monitoring preparations of hgDNA from volunteers and a strategy is being developed to test for the presence of processed pseudogenes for EPO if a positive result from developed cDNA-EPO assays is observed in hgDNA.
Finally, it is important to note, that as the developed approach was evaluated in a simple in vitro model system, the sensitivity and specificity of the developed assays may differ in 'real' samples of athletes' blood. Therefore, further research is necessary to optimize other factors with potential to impact on the overall uncertainty of gene doping detection by this approach. In particular, more studies will be required to establish optimal protocols for sample collection, handling, preparation and storage and for DNA extraction and purification. These areas are being currently addressed in research carried out in our laboratory.
Materials and methods

Materials
Salmon testes DNA, lambda DNA and hgDNA were purchased from Merck (Darmstadt, Germany), Promega (Madison, WI, USA) and AVIVA Systems Biology (San Diego, CA, USA), respectively. Brilliant II QPCR Master Mix was from Stratagene (Cedar Creek, TX, USA), whereas SYBR Green PCR and TaqMan Universal PCR Master Mixes were from Applied Biosystems (Warrington, UK, for the former, or, manufactured by Roche, Branchburg, NJ, USA, for the latter). TaqMan gene expression assay for EPO (Assay ID Hs01071097_m1) was purchased from Applied Biosystems (Foster City, CA, USA) and was used according to the manufacturer's instruction. Primers were ordered from GeneWorks (SA, Australia), Sigma-Aldrich (Singapore) or Operon (Cologne, Germany), whereas hydrolysis probes were purchased from Biosearch Technologies (Novato, CA, USA) or Sigma-Aldrich. All PCR primers and probes were of high-performance liquid chromatography purity, whereas sequencing primers were of PCR/sequencing purity. The probes contained FAM (5-carboxyfluorescein) fluorophore at 5 0 -end and 'minor groove binder' (for Assay Hs01071097_m1) or 'black hole quencher' at 3 0 -end. Restriction enzymes EcoRV and HpaI were from Promega. Unless specified, all DNA dilutions were prepared in Tris-EDTA buffer (10 mM Tris, 0.1 mM EDTA, pH 8.0). All other reagents were of molecular biology grade or required purity.
Preparation of plasmid containing human EPO transgene
Plasmid containing human EPO gene (intronless open reading frame, pDNA-EPO) was prepared from lyophilized GT100 Escherichia coli bacteria transformed by pORF5-hEPO (InvivoGen, San Diego, CA, USA). For that, transformed bacteria were propagated, the plasmid was isolated using Plasmid mega kit (QIAGEN GmbH, Hilden, Germany) and quantified in pg ml À1 using a PicoGreen assay with the PicoGreen reagent (Molecular Probes, Invitrogen, Eugene, OR, USA) with lambda DNA as a standard. The number of copies of pDNA-EPO per ml was calculated using the weight of one mole of the plasmid (calculated from the plasmid length and its sequence, both provided by the supplier) and the Avogadro number for the number of pDNA-EPO copies per one mole. The stock of the isolated pDNA-EPO contained B555 pg of pDNA-EPO per ml, which corresponded to B144 Â 10 9 copies of pDNA-EPO per ml. To confirm the integrity of pDNA-EPO and cDNA-EPO, the purified plasmid was digested using restriction enzymes EcoRV and HpaI and analyzed using agarose gel electrophoresis. The integrity and identity of the cDNA-EPO sequence in the isolated plasmid was verified by sequencing using several forward and reverse primers designed using Primer3, 21 Integrated DNA Technologies PrimerQuest (http://www.idtdna. com/Scitools/Applications/PrimerQuest/) and Autoprime 22 software. Sequencing confirmed the transgene identity as cDNA-EPO, but revealed a mismatch for a single base at position 606, in which a thymine nucleotide was identified instead of the expected guanine nucleotide. The mismatch was later confirmed by the supplier.
Real-time PCR assay design
Suitable PCR assays for analysis of cDNA-EPO (GenBank accession NM_000799.2, CCDS5705.1) were Erythropoietin gene doping detection A Baoutina et al
